Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Kathelijn Fischer, MD PhD MSc, Pratima Chowdary, FRCPath, MRCPath, MRCP, MD, Peter Collins, MD, Amy Cotterill, PhD, Barbara Konkle, MD, Victor S. Blanchette, FRCP, FRCPC, Steven W. Pipe, MD, Martin Wolfsegger, Cstat (RSS), Werner Engl, PhD Cstat, Jimena V Goldstine, PhD, Leonard A. Valentino, MD FAAP, Gerald Spotts, PhD

Blood (2016) 128 (22): 2576.

https://doi.org/10.1182/blood.V128.22.2576.2576

Published: 2016

Journal Articles

No Association Between Platelet Function and Hemophilia B Phenotype

Roger E.G. Schutgens, MD PhD, Esther R. van Bladel, MD PhD, Kathelijn Fischer, MD PhD MSC, Mark Roest, PhD, Rolf Urbanus, PhD

Blood (2014) 124 (21): 4994.

https://doi.org/10.1182/blood.V124.21.4994.4994

Published: 2014

Journal Articles

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

Menchen Xi, Tamara Navarro-Ruan, MLIS. MD, Sunil Mammen, Victor S. Blanchette, MD FRCPC, Cedric R. Hermans, MD PhD, Massimo Morfini, MD, Peter W. Collins, MD, Kathelijn Fischer, MD PhD MSC, Ellis J. Neufeld, Guy Young, MD, Kaan Kavakli, MD, Paolo Radossi, MD, Amy Dunn, Lehana Thabane, PhD, Alfonso Iorio, MD PhD

Blood (2014) 124 (21): 2818.

https://doi.org/10.1182/blood.V124.21.2818.2818

Published: 2014

Journal Articles

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Gerald Spotts, PhD, Steven W. Pipe, MD, Erik Berntorp, MD PhD, Peter W. Collins, MD, Victor S. Blanchette, MD FRCPC, Kathelijn Fischer, MD PhD MSC, MyungShin Oh, Leonard A. Valentino, MD FAAP

Blood (2014) 124 (21): 689.

https://doi.org/10.1182/blood.V124.21.689.689

Published: 2014

Journal Articles

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Kathelijn Fischer, MD, PhD, Roshni Kulkarni, MD, Myles Bradbury, MD, Margaret V. Ragni, MD, MPH, Savita Rangarajan, MBBS, FRCP, FRCPath, Yingwen Dong, PhD, Shuanglian Li, MD, PhD, Haiyan Jiang, PhD, Karen Nugent, MSc, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 3599.

https://doi.org/10.1182/blood.V122.21.3599.3599

Published: 2013

Journal Articles

Protected by Nature: Effects of Exercise In Non-Severe Haemophilia Patients

Ingrid E.M. den Uijl, DVM, MSc, Wim G Groen, Msc, Jan Jaap van der Net, PhD, Diederick E Grobbee, PhD, Philip G de Groot, PhD, Kathelijn Fischer, MD, PhD

Blood (2010) 116 (21): 545.

https://doi.org/10.1182/blood.V116.21.545.545

Published: 2010

Journal Articles

Sequential Combined Bypassing Therapy (SCBT) Is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Haemophilia and Inhibitors.

Alessandro Gringeri, MD, MSc, Kathelijn Fischer, MD, PhD, MSc, Anastasia Karafoulidou, MD, Robert Klamroth, MD, Maria Fernanda Lopez, MD, Maria Elisa Mancuso, MD

Blood (2009) 114 (22): 1294.

https://doi.org/10.1182/blood.V114.22.1294.1294

Published: 2009

Journal Articles

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

Myungshin Oh, PhD, Sven Björkman, PhD, Phillip Schroth, Sandor Fritsch, PhD, Peter Collins, MD, Kathelijn Fischer, MD, PhD, MSc, Victor S. Blanchette, MD, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2009) 114 (22): 3492.

https://doi.org/10.1182/blood.V114.22.3492.3492

Published: 2009

Journal Articles

Value of Additional CD19 Lymphocyte Counts for the Detection of B-CLL in a Primary Health Care Laboratory

Doreen te Raa, MD, Kathelijn Fischer, MD, PhD, Wim Verweij, Douwe Biesma, MD, PhD

Blood (2008) 112 (11): 4184.

https://doi.org/10.1182/blood.V112.11.4184.4184

Published: 2008

Journal Articles

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

Peter Collins, Kathelijn Fischer, MD, PhD, MSC, Victor S. Blanchette, FRCP, Sven Björkman, Myungshin Oh, Phillip Schroth, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Sandor Fritsch, Bruce M. Ewenstein, MD, PhD

Blood (2008) 112 (11): 1222.

https://doi.org/10.1182/blood.V112.11.1222.1222

Published: 2008

Journal Articles

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Kathelijn Fischer, MD, PhD, Peter Collins, MD, Jan Astermark, MD, Victor S. Blanchette, MD, Sven Bjorkman, PhD, Myungshin Oh, PhD, Phillip Schroth, Sandor Fritsch, PhD, Kathleen M. Casey, PhD, Gerald Spotts, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2007) 110 (11): 1145.

https://doi.org/10.1182/blood.V110.11.1145.1145

Published: 2007

Journal Articles

Who Gets Inhibitors? Predicting Inhibitory Antibodies in Children with Severe Hemophilia A.

Petra C. ter Avest, MD, Kathelijn Fischer, MD, PhD, Elena Santagostino, MD, PhD, Marijke H. van den Berg, MD, PhD, Johanna G. van der Bom, MD, PhD

Blood (2007) 110 (11): 1158.

https://doi.org/10.1182/blood.V110.11.1158.1158

Published: 2007

Journal Articles

Outcome Assessment in Hemophilia: A Pilot Study on Correlation of Different Instruments.

Kathelijn Fischer, MD, PhD, Frank R. Van Genderen, MSc, PhD, Piet De Kleijn, Marijke Van den Berg, MD, PhD

Blood (2006) 108 (11): 1032.

https://doi.org/10.1182/blood.V108.11.1032.1032

Published: 2006

Journal Articles

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

Peter W. Collins, MD, Victor Blanchette, MD, Kathelijn Fischer, MD, Jan Astermark, MD, Phillip Schroth, Sandor Fritsch, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2006) 108 (11): 1041.

https://doi.org/10.1182/blood.V108.11.1041.1041

Published: 2006

Journal Articles

Variability in Bleeding Pattern of Severe Hemophilia.

Karin van Dijk, MD, Kathelijn Fischer, MD, PhD, Johanna G. van der Bom, MD, PhD, Eveline P. Mauser-Bunschoten, MD, PhD, Goris Roosendaal, MD, PhD, H. Marijke van den Berg, MD, PhD

Blood (2004) 104 (11): 3094.

https://doi.org/10.1182/blood.V104.11.3094.3094

Published: 2004

Journal Articles

Incidence and Outcome of Discontinuation of Prophylactic Treatment among Young Adults with Severe Hemophilia.

Karin van Dijk, MD, Kathelijn Fischer, MD, PhD, Johanna G. van der Bom, MD, PhD, Elma Scheibel, MD, PhD, Jørgen Ingerslev, MD, PhD, H. Marijke van den Berg, MD, PhD

Blood (2004) 104 (11): 3086.

https://doi.org/10.1182/blood.V104.11.3086.3086

Published: 2004

NARROW

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

No Association Between Platelet Function and Hemophilia B Phenotype

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Protected by Nature: Effects of Exercise In Non-Severe Haemophilia Patients

Sequential Combined Bypassing Therapy (SCBT) Is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Haemophilia and Inhibitors.

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

Value of Additional CD19 Lymphocyte Counts for the Detection of B-CLL in a Primary Health Care Laboratory

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

Who Gets Inhibitors? Predicting Inhibitory Antibodies in Children with Severe Hemophilia A.

Outcome Assessment in Hemophilia: A Pilot Study on Correlation of Different Instruments.

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

Variability in Bleeding Pattern of Severe Hemophilia.

Incidence and Outcome of Discontinuation of Prophylactic Treatment among Young Adults with Severe Hemophilia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only